NO20063026L - Antistoffer - Google Patents

Antistoffer

Info

Publication number
NO20063026L
NO20063026L NO20063026A NO20063026A NO20063026L NO 20063026 L NO20063026 L NO 20063026L NO 20063026 A NO20063026 A NO 20063026A NO 20063026 A NO20063026 A NO 20063026A NO 20063026 L NO20063026 L NO 20063026L
Authority
NO
Norway
Prior art keywords
binds
amino acid
acid sequence
fragment
antibodies
Prior art date
Application number
NO20063026A
Other languages
English (en)
Inventor
Christer Nordstedt
Tom Goldschmidt
Maria Henderikx
Rene Hoet
Henricus Hoogenboom
Simon Hufton
Christin V Andersson
Johanna Lindquist
Dan Sunnemark
Sergy Leonov
Original Assignee
Dyax Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dyax Corp filed Critical Dyax Corp
Publication of NO20063026L publication Critical patent/NO20063026L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Humant antistoffragment, hvilket antistoff eller fragment: (i) binder til et polypeptid som har aminosyresekvensen vist i SEKV.1D.NR.: I av det C-terminale domene av apolipoprotein E (ApoE-CTD) eller aminosyresekvensen av en del derav; og (ii) binder til humane plakk.
NO20063026A 2003-11-28 2006-06-28 Antistoffer NO20063026L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52517403P 2003-11-28 2003-11-28
PCT/EP2004/013426 WO2005051998A2 (en) 2003-11-28 2004-11-26 Antibodies binding to a c-terminal fragment of apolipoprotein e

Publications (1)

Publication Number Publication Date
NO20063026L true NO20063026L (no) 2006-08-28

Family

ID=33564077

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20063026A NO20063026L (no) 2003-11-28 2006-06-28 Antistoffer

Country Status (16)

Country Link
US (1) US8058016B2 (no)
EP (2) EP2343318A3 (no)
JP (1) JP4869074B2 (no)
KR (2) KR20060120161A (no)
CN (1) CN1890266B (no)
AR (1) AR047729A1 (no)
AU (1) AU2004293180B2 (no)
BR (1) BRPI0417023A (no)
CA (1) CA2547675A1 (no)
GB (1) GB2408508A (no)
IL (1) IL175608A0 (no)
NO (1) NO20063026L (no)
RU (1) RU2006122946A (no)
TW (1) TW200530267A (no)
UY (1) UY28641A1 (no)
WO (1) WO2005051998A2 (no)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
DE60335552D1 (de) 2002-09-11 2011-02-10 Genentech Inc Neue zusammensetzung und verfahren zur behandlung von immunerkrankungen
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
WO2005058938A2 (en) 2003-12-15 2005-06-30 The Regents Of The University Of California Helical synthetic peptides that stimulate cellular cholesterol efflux
KR20180058863A (ko) 2005-11-30 2018-06-01 애브비 인코포레이티드 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
RU2442793C2 (ru) 2005-11-30 2012-02-20 Эбботт Лэборетриз АНТИТЕЛА ПРОТИВ ГЛОБУЛОМЕРА Аβ, ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ЧАСТИ, СООТВЕТСТВУЮЩИЕ ГИБРИДОМЫ, НУКЛЕИНОВЫЕ КИСЛОТЫ, ВЕКТОРЫ, КЛЕТКИ-ХОЗЯЕВА, СПОСОБЫ ПОЛУЧЕНИЯ УКАЗАННЫХ АНТИТЕЛ, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ АНТИТЕЛА, ПРИМЕНЕНИЯ УКАЗАННЫХ АНТИТЕЛ И СПОСОБЫ ИСПОЛЬЗОВАНИЯ УКАЗАННЫХ АНТИТЕЛ
GB0621513D0 (en) * 2006-10-30 2006-12-06 Domantis Ltd Novel polypeptides and uses thereof
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
WO2008084402A2 (en) * 2007-01-11 2008-07-17 Philipps-Universitaet Marburg Diagnosis and treatment of alzheimer's and other neurodementing diseases
WO2008104386A2 (en) 2007-02-27 2008-09-04 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
CN103275216B (zh) 2007-03-12 2015-05-06 艾斯巴技术-诺华有限责任公司 单链抗体的基于序列的工程改造和最优化
EP2164961B1 (en) 2007-06-25 2015-01-07 ESBATech, an Alcon Biomedical Research Unit LLC Sequence based engineering and optimization of single chain antibodies
CN102838673B (zh) * 2007-06-25 2016-05-11 艾斯巴技术-诺华有限责任公司 修饰抗体的方法和具有改善的功能性质的修饰抗体
US8173130B2 (en) 2007-09-05 2012-05-08 Inotek Pharmaceuticals Corporation Antibodies against flagellin and uses thereof
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
KR101855381B1 (ko) 2008-04-09 2018-05-09 제넨테크, 인크. 면역 관련 질병의 치료를 위한 신규한 조성물 및 방법
ES2684475T3 (es) 2010-04-15 2018-10-03 Abbvie Inc. Proteínas que se unen a beta amiloide
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
MX2013006116A (es) * 2010-12-02 2013-10-17 Univ Washington Tratamiento de sintomas asociados a placa amiloide.
CN102863525B (zh) * 2011-07-04 2014-06-04 武汉大学 一种重组人apoE拟肽及制备方法和应用
EP3021869B1 (en) 2013-07-16 2020-07-15 F. Hoffmann-La Roche AG Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors
CN108137691B (zh) 2015-09-02 2021-10-19 耶路撒冷希伯来大学伊萨姆研究发展有限公司 特异性针对人类t-细胞免疫球蛋白和itim结构域(tigit)的抗体
AU2016325610B2 (en) 2015-09-25 2019-10-10 Genentech, Inc. Anti-TIGIT antibodies and methods of use
US10894830B2 (en) * 2015-11-03 2021-01-19 Janssen Biotech, Inc. Antibodies specifically binding PD-1, TIM-3 or PD-1 and TIM-3 and their uses
AU2017350947B2 (en) 2016-10-28 2024-02-15 Washington University Anti-ApoE antibodies
EP3597222A1 (en) * 2018-07-16 2020-01-22 Easemedcontrol R & D GmbH & Co KG Treatment and diagnosis of unresolved inflammatory diseases
US20220119502A1 (en) * 2019-02-28 2022-04-21 Ann And Robert H. Lurie Children's Hospital Of Chicago Kawasaki disease antibodies identify hepacivirus peptides
EP3757121A1 (en) * 2019-06-28 2020-12-30 Eisai R&D Management Co., Ltd. Apolipoprotein e fragments
US11911414B2 (en) * 2020-03-27 2024-02-27 Epivax Inc. Regulatory T cell epitopes

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE262592T1 (de) * 1992-10-13 2004-04-15 Univ Duke Verfahren zum nachweis der alzheimer krankheit
US6107045A (en) 1994-06-30 2000-08-22 Oklahoma Medical Research Foundation Antibodies to lipoproteins and apolipoproteins and methods of use thereof
US5807978A (en) 1995-06-07 1998-09-15 Kokolus; William J. Immunogenic peptides of prostate specific antigen
US6046381A (en) 1998-04-30 2000-04-04 The Regents Of The University Of California Apolipoprotein E transgenic mice and assay methods
JP2002530122A (ja) * 1998-11-25 2002-09-17 サイオス インコーポレイテッド アミロイド関連疾患の予防及び治療
ATE398177T1 (de) * 2000-11-03 2008-07-15 David Gladstone Inst Verfahren zur behandlung von erkrankungen im zusammenhang mit apoe
WO2002054080A2 (en) * 2000-12-29 2002-07-11 Oxford Glycosciences (Uk) Ltd. Proteins, genes and their use for diagnosis and treatment of vascular response
EP1434053B1 (en) * 2001-10-04 2008-03-26 Immuno-Biological Laboratories Co., Ltd. Reagent for detecting risk factor for alzheimer's disease, detection kit therefor and method of detecting risk factor for alzheimer's disease using the same
EP1543331B1 (en) * 2002-07-30 2009-02-11 The J. David Gladstone Institutes Method of diagnosing alzheimer's disease

Also Published As

Publication number Publication date
UY28641A1 (es) 2005-06-30
KR20060120161A (ko) 2006-11-24
EP1687336A2 (en) 2006-08-09
AU2004293180B2 (en) 2011-09-15
WO2005051998A2 (en) 2005-06-09
GB2408508A (en) 2005-06-01
CN1890266B (zh) 2012-10-03
AU2004293180A1 (en) 2005-06-09
US8058016B2 (en) 2011-11-15
WO2005051998A3 (en) 2007-07-26
GB0426043D0 (en) 2004-12-29
US20100061993A1 (en) 2010-03-11
CN1890266A (zh) 2007-01-03
JP4869074B2 (ja) 2012-02-01
BRPI0417023A (pt) 2007-02-21
TW200530267A (en) 2005-09-16
IL175608A0 (en) 2006-09-05
AR047729A1 (es) 2006-02-15
RU2006122946A (ru) 2008-01-10
CA2547675A1 (en) 2005-06-09
JP2008502311A (ja) 2008-01-31
KR20120108061A (ko) 2012-10-04
EP2343318A2 (en) 2011-07-13
EP2343318A3 (en) 2013-02-27

Similar Documents

Publication Publication Date Title
NO20063026L (no) Antistoffer
CY1118037T1 (el) Αντισωματα εναντι του αβητα και h χρηση τους
DE60238993D1 (de) Hybrid und tandemproteine von neisseria sp
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
RS54133B1 (en) ANTI-IL-6 ANTIBODIES, PREPARATIONS, PREPARATION AND USE PROCEDURES
AR047347A1 (es) Miembros de la familia cry9 de bacillus
WO2005087811A3 (en) Estrogen receptors and methods of use
EA200700136A1 (ru) Анти-cd154-антитела
MX348154B (es) Anticuerpos de enlace a il-1-beta y fragmentos de los mismos.
PE20120532A1 (es) ANTICUERPOS ANTI-ActRIIB
ATE368688T1 (de) Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
ATE495247T1 (de) Chromoprotein und fluoroproteine
DE602006014140D1 (de) Mit scytovirin der domäne 1 verwandte polypeptide
DK1913020T3 (da) Immunogene konstrukter
ATE543906T1 (de) Antigen von streptococcus aus der b-gruppe
DK1368372T3 (da) Peptid med affinitet til det virale gp120-protein samt anvendelse deraf
EA200901441A1 (ru) Новые молекулы антител и нуклеиновых кислот, связывающиеся с грибным белком теплового шока hsp90
ATE387629T1 (de) Gemeinsame epitope von antigenen aus einer multigen-familie
DK1117682T3 (da) Chi-conotoksin-peptider som inhibitorer af neuronale amintransportere
ATE441865T1 (de) Neue polypeptide zur in-vintro-isolierung und vorbeugung von infektionen mit legionella pneumophila
ATE342978T1 (de) Einkettige polypeptide enthaltend n-terminale troponin i fragmente und troponin c
DE602006017806D1 (de) Behandlung von neurodegeneration
CY1111630T1 (el) Παραγωγα κυτοκινων
NO20082864L (no) Nytt polypeptid med esteraseaktivitet og rekombinant esterase samt anvendelse derav
NO20082810L (no) Vaksine, og anvendelse av samme

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application